Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;10(3):791-818.
doi: 10.3233/JPD-201965.

Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk

Affiliations
Free PMC article
Review

Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk

Rakez Kayed et al. J Parkinsons Dis. 2020.
Free PMC article

Abstract

There is growing recognition in the field of neurodegenerative diseases that mixed proteinopathies are occurring at greater frequency than originally thought. This is particularly true for three amyloid proteins defining most of these neurological disorders, amyloid-beta (Aβ), tau, and alpha-synuclein (αSyn). The co-existence and often co-localization of aggregated forms of these proteins has led to the emergence of concepts positing molecular interactions and cross-seeding between Aβ, tau, and αSyn aggregates. Amongst this trio, αSyn has received particular attention in this context during recent years due to its ability to modulate Aβ and tau aggregation in vivo, to interact at a molecular level with Aβ and tau in vivo and to cross-seed tau in mice. Here we provide a comprehensive, critical, and accessible review about the expression, role and nature of endogenous soluble αSyn oligomers because of recent developments in the understanding of αSyn multimerization, misfolding, aggregation, cross-talk, spreading and cross-seeding in neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, and Huntington's disease. We will also discuss our current understanding about the relative toxicity of endogenous αSyn oligomers in vivo and in vitro, and introduce potential opportunities to counter their deleterious effects.

Keywords: Amyloid-β; aggregation; cross-seeding; cross-talk; multimer; neurodegenerative disease; oligomer; tau; α-synuclein.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
Proposed model of αSyn assemblies in health (‘multimers’) and disease (‘oligomers’). Schematic of one cell and extracellular space. Under physiological conditions (in blue, bottom left), αSyn comes off the ribosome as a soluble unfolded monomer (blue ‘αSyn’), which forms helical monomers (blue circle) upon getting in contact with vesicle membranes. Helical monomers at membranes may assemble into metastable physiological multimers (low-n assemblies in blue) that eventually fall apart again, initiating a new cycle. Under stress of pathological conditions (in pink shading, starting bottom middle), excess of unfolded or helical membrane-bound αSyn has been proposed to be the starting point for pathological aggregation into oligomers including dimers, tetramers, annular protofibrils and larger oligomers. We propose that two distinct misfolded states of αSyn lead to two distinct aggregation pathways, one forming amyloid fibrils (ON pathway; A11/OC+), and one forming large non-fibrillar αSyn oligomers (OFF pathway, A11+/OC). Endogenous oligomeric αSyn are likely to be enriched for β-sheet motifs. The endpoint of intracellular aggregation is the so-called Lewy body (top left). Mixed intracellular aggregates have also been reported in particular with tau (red baton), although the exact αSyn oligomer interacting with tau is unknown (indicated by ‘?’). Cross-talks between αSyn species and huntingtin oligomers (Htt, orange hexagons) have also been advanced but require confirmation. Oligomers of αSyn may be released into the extracellular space by an ill-defined mechanism (right). There, they may further aggregate, which may include the formation of mixed aggregates, with amyloid-β peptides (Aβ, purple stars) in particular with which αSyn can form hybrid αSyn/Aβ oligomers. Extracellular aggregates may be taken up by cells and released into the cytosol where they may in turn ‘seed’ αSyn aggregation. Release, uptake and seeding of intracellular pathology might be underlying the phenomenon of αSyn spread and release might correspond to a possible protective mechanism adopted by cells to maintain cellular proteostasis.
Fig. 2
Fig. 2
Relationships between 28-, 35- and 55 kDa αSyn oligomers in human brain tissue from cognitively intact subjects and subjects with AD within the ROS cohort. Regression analyses and quantile density contours for pair-wise comparisons between 35 kDa (A) or 28 kDa (B) dimeric αSyn and the ∼55–56 kDa putative αSyn tetramer detected in the intracellular-enriched fraction (IC). All species were detected with the monoclonal antibody 4D6. NCI, no cognitive impairment; AD, Alzheimer’s disease; ROS, Religious Orders Study.

Similar articles

Cited by

References

    1. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10, S10–S17. - PubMed
    1. Arnold SE, Toledo JB, Appleby DH, Xie SX, Wang L-S, Baek Y, Wolk DA, Lee EB, Miller BL, Lee VM-Y, Trojanowski JQ (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521, 4339–4355. - PMC - PubMed
    1. Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM-Y, Trojanowski JQ (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181–2193. - PMC - PubMed
    1. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, Brownstein MJ, Tagle DA (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett 289, 29–32. - PubMed
    1. Tomás-Zapico C, Díez-Zaera M, Ferrer I, Gómez-Ramos P, Morán MA, Miras-Portugal MT, Díaz-Hernández M, Lucas JJ (2012) α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington’s disease. Hum Mol Genet 21, 495–510. - PubMed

Publication types

MeSH terms

Substances